DDInter255 DDInter875
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
Busulfan {u} (Compound) binds {v} (Gene) MGST2
Busulfan {u} (Compound) upregulates {v} (Gene) DUSP11
Busulfan {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Busulfan {u} (Compound) downregulates {v} (Gene) MRPL19
Busulfan {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Busulfan (Compound) treats hematologic cancer (Disease)
Busulfan (Compound) binds MGST2 (Gene)
Busulfan (Compound) upregulates DUSP11 (Gene)
Busulfan (Compound) is included by Alkylating Activity (Pharmacologic Class)
Busulfan (Compound) downregulates MRPL19 (Gene)
Busulfan (Compound) causes Dermatitis bullous (Side Effect)